Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,769
Total Claims
$1.5M
Drug Cost
1,003
Beneficiaries
$1,476
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
+31%
Cost per patient vs peers
$1,476 vs $1,128 avg
+21%
Brand preference vs peers
10.2% vs 8.4% avg
Brand vs Generic
Brand: 2,089 claims · $1.1M
Generic: 18,402 claims · $317K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 125 | $139K |
| Apixaban | 177 | $123K |
| Budesonide/Formoterol Fumarate | 139 | $65K |
| Mirabegron | 66 | $60K |
| Linaclotide | 97 | $56K |
| Sacubitril/Valsartan | 29 | $52K |
| Insulin Glargine,hum.Rec.Anlog | 124 | $41K |
| Rivaroxaban | 43 | $38K |
| Dulaglutide | 27 | $37K |
| Insulin Detemir | 64 | $34K |
| Sitagliptin Phos/Metformin Hcl | 30 | $32K |
| Insulin Glargine,hum.Rec.Anlog | 55 | $28K |
| Semaglutide | 25 | $27K |
| Linagliptin | 14 | $24K |
| Icosapent Ethyl | 65 | $22K |
Prescribing Profile
Patient Profile
75
Avg Age
62%
Female
2.05
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data